Ethics of clinical trials placebo

Unfortunately, these Right to Try laws could have a negative effect on clinical trials. Patients may be more likely to utilize the Right to Try option rather than signing up for a clinical trial. That said, their effects on participation in clinical trials should be taken into account.

There are a growing number of medical professionals who consider the use of placebos unethical, especially when the efficacy of the treatment has already been proven. She is an avid goal setter and achiever. Tweet her your favorite health tips JenniferELandis.

Your email address will not be published. Save my name, email, and website in this browser for the next time I comment. This site uses Akismet to reduce spam.

Learn how your comment data is processed. But those same placebos may end up providing information that could protect or save lives once the drug completes its clinical trials. Why use placebos in clinical trials? Related Content: Five Reasons Why You Should Participate in Clinical Trials Ethical concerns for placebo use There are multiple schools of thought when it comes to the ethics of placebo use in clinical trials. Greater risks than ethics Additionally, though this has little impact on ethics, studies completed without a placebo group might not have all the information they need to safely prescribe and market a drug.

Despite this, the development and use in the clinics of targeted agents is as yet underexplored in its ethical consequences. From the point of view of the clinical practice, the most serious issues are raised by concerns of distributive justice, especially face the escalating costs of molecular agents [ 33 ].

However, the focus of this review is the context of clinical research, and of clinical trials in particular. As a matter of fact, the testing of targeted agents is an even more neglected topic in the ethical literature; in the following, the author will present some observations based on original research. The reader should be warned, though, that the complexity and breadth of the issues involved far exceeds the scope of this review.

When patients that have the same kind of tumour, but harbouring different molecular lesions, are exposed to a targeted compound, the response can vary dramatically to the point that not only the magnitude, but also the direction of the treatment effect may be different across molecularly identified subgroups. This is particularly relevant for the testing of such drugs, as it means that the beneficial effect of the targeted agent in trial is often restricted to a small class of the initially eligible patients, and the class of patients that would benefit often cannot be determined prior to beginning the study [ 34 ].

Thus, in a study testing a targeted agent, only a small fraction of the participating patients have a prospect to benefit from the experimental treatment at all. While apparently this seems true of conventional RCTs as well, a closer inspection reveals the ethical issue as specific of targeted therapies. In the case of a treatment that has universal application, like a conventional cytotoxic agent, whether the trial is successful or not, it will have established a conclusion that is relevant also for the patients that were participating—this prospectively justifies their participation.

However, this is admittedly not the case for participants in a targeted therapy trial—at the outset of the trial, it is known that the conclusion about the new therapy will at best have a relevance only for a small fraction of these patients. This unprecedented ethical issue can indeed be alleviated in case there exist means—such as reliable tests or biomarkers—to single out for trial participation only those patients which are likely to respond; at the time being, however, this is unfortunately not often the case.

Furthermore, the possibility of conducting trials only on a highly selected population of patients raises a new set of concerns. It has been argued that precision medicine calls for a shift in the drug testing paradigm, from the current one based on large RCTs and the centrality of statistical evidence, to one based on shorter, smaller trials that combine the statistical evidence from the trial with causal knowledge coming from the lab [ 35 ].

Prima facie such a shift would be beneficial in terms of the ethics of the targeted trials, since small trials expose only a minimum number of patients to the controversial risks and burdens of trial participation. Indeed, there seems to be a strong ethical rationale in having trials involve the least number of patients necessary to achieve a conclusion. However, the issue is with the reliability of the conclusions that can be arrived at through such trials.

If the trial is designed in a way that prevents the achievement of its ultimate scientific purpose, i. Underpowered trials—trials with insufficient participants to achieve adequate statistical power—have repeatedly been denounced as unethical on these grounds [ 36 ], and recent work shows [ 37 ] that the same argument could indeed be raised against small, biomarkerdriven trials of targeted therapies.

The ethical issues just presented in relation to the testing of targeted therapies seem ultimately to boil down to a problem of conflicting evidential standards. What needs to be resolved is whether the evidence to prove a personalised therapy efficacious differs, and in what ways, from the evidence that is needed to put conventional medicines to test. Only when this epistemic point is clarified, it will be possible to qualify the ethical issues discussed above and possibly solve them.

Thus, it seems that the ethics of targeted trials cannot be properly adjudicated until the evidential peculiarities of personalised therapies find a firm place in the evidential paradigm of medicine. Whether this requires a paradigm shift or just a small adjustment is, however, an entirely different and still open question [ 39 ].

The distinctive issues that are faced as oncology transitions to a precision medicine paradigm, as well as the other issues analyzed in this review, testify that the ethics of clinical trials becomes increasingly complex to evaluate as clinical research progresses, as research questions become more sophisticated, and as the research context as a whole grows to an increasing level of interplay among diverse actors. The ethical discourse has to keep abreast of these changes, in order to provide an adequate guidance for medical research in the future.

National Center for Biotechnology Information , U. Journal List Ecancermedicalscience v. Published online Jan Cecilia Nardini. Author information Article notes Copyright and License information Disclaimer. Correspondence to: Cecilia Nardini. Received Oct This article has been cited by other articles in PMC.

Abstract Over the past decades, randomised controlled trials RCTs have prevailed over clinical judgement, case reports, and observational studies and became the gold evidential standard in medicine. Keywords: ethics, RCTs, research, personalized medicine, precision medicine. Introduction: research and experimentation on human subjects Research involving human subjects has anything but a glorious legacy.

The randomised controlled trial The randomised controlled trial RCT consists, in its most conventional form, in a comparison of the action of the experimental treatment versus the untreated progression of an illness under study. The main ethical issues surrounding RCTs The general problem with the ethics of clinical trials stems from the fact that those who stand to gain from the trial results are not the same that bear the risk and burden of trial participation.

Participation and informed consent The past history of medical research features several episodes in which the burdens of research participation were placed disproportionally on trial participants, either by deceiving them with the promise of a cure or by deliberately concealing that they were taking part in research. Use of placebo and deception Personal expectations about treatment entertained by both patients and investigators may play an unexpectedly large role on the progress of a therapy.

Randomisation and blinding, and equipoise RCTs involve, by definition, randomisation and often blindfolding of participants. Navigating between exploitation and overprotection of patients As discussed in opening the section, in clinical research, there exists a gap between those who are exposed to the risk of a medical intervention—the trial participants—and those who are the intended beneficiaries of the trial results—future patients and society at large. An outlook on oncological research The issues discussed in this review stem from general features of clinical research and the RCT methodology, such as the need to subject patients to blindfolding and random allocation between treatment arms, or the point that medical research and practice respond to different ethical standards.

Conclusion The distinctive issues that are faced as oncology transitions to a precision medicine paradigm, as well as the other issues analyzed in this review, testify that the ethics of clinical trials becomes increasingly complex to evaluate as clinical research progresses, as research questions become more sophisticated, and as the research context as a whole grows to an increasing level of interplay among diverse actors.

References 1. Jones JH. New York: The Free Press; []. The Nuremberg Code. Trials of war criminals before the Nuremberg military tribunals under control council law. World Medical Association. Declaration of Helsinki, 6th revision. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. Howick JH. The Philosophy of Evidence-Based Medicine. London: Wiley-Blackwell; Teira D, Reiss J.

Goodman SN. Toward evidence-based medical statistics. Ann Intern Med. Sackett DL, et al. New York: Churchill Livingstone; Berg JW, et al. New York: Oxford University Press; Informed consent: is it a myth? Emanuel EJ, et al. Oxford: Oxford University Press; Miller F, Brody H. A critique of clinical equipoise: therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep. Wendler D, Miller F. Deception in the pursuit of science.

Arch Intern Med. Deng C, et al. Challenges of clinical trial design when there is lack of clinical equipoise: use of a response conditional crossover design. J Neurol. Temple R, Ellenberg SS.

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Anderson JA. The ethics and science of placebo-controlled trials: assay sensitivity and the Duhem—Quine thesis. J Med Philos. Howick J. Finally guidelines are presented according to which the placebo may be used for clinical purposes.

It is suggested that in select cases, use of the placebo may even be morally imperative. The argument is illustrated by three case vignettes. The two situations do, however, differ. In clinical practice, the physician prescribes a placebo in the hope that it will produce a therapeutic effect. In research, on the other hand, the physician prescribes a placebo in the hope that it will produce no therapeutic effect. The ethical implications for these two scenarios are different and need to be considered separately.

We will focus on the less commonly examined area of the use of the placebo in daily practice. The placebo is not easily defined. Indeed, some have despaired of ever finding an adequate definition for the term. These diverse features of medical and paramedical care can certainly be usefully studied in their own right, but to subsume them under an all encompassing placebo rubric would be conceptually sloppy and heuristically befuddling.

Exposing the fallacy of this approach does not entail an intricate philosophical discursion; the results of recent research into the placebo effect will suffice. If induced by expectation, placebo analgesia will be mediated by endorphins; if influenced by non-opioid based conditioning, endorphins will not be involved.

The mind, in brief, may have a quite specific effect on the body. In the case of the placebo, this effect transpires in a top down direction, from a level of greater to lesser complexity, from the level of the person to that of the organ system, organ or cell.

Physicians will not uncommonly offer a placebo to a patient. The effectiveness of the placebo has been claimed for many fields in medicine, such as surgery, 9 cardiology, 10 psychiatry, 11 primary care, 12 and elsewhere.

In double blind, randomised controlled trials, placebo treated groups routinely show improvement for a wide range of maladies and in widely ranging degrees. Nevertheless, some have wondered whether these effects are justifiably attributed to the placebo, or whether they reflect other processes at work, such as regression to the mean or the natural progression of illness.

These findings have already led some to dismiss the placebo effect as a myth. The meta-analytic methods employed by Hrobjartsson and Gotzsche, 13 in particular the inclusion of different types of studies of diverse disorders in a single analysis, may be questioned. The work of Benedetti and colleagues, already referred to, delineates a placebo effect, beyond a no treatment effect, not only for analgesia, 6 which Hrobjartsson and Gotzsche 13 acknowledge, but also for the production of respiratory responses as confirmed by objective measures.

First we will provide two clinical vignettes derived from actual practice, which will serve as a basis for our further discussion. A 45 year old man suffering for many years from diabetes and hypertension underwent a second leg amputation. Severe pain following the surgery was treated with injections of intramuscular pethidine, an opioid analgesic. His pain virtually unabated, the patient demanded additional therapy.

The staff decided to administer, in addition to pethidine, intramuscular saline. They explained to the patient that injectible saline had been used as an effective painkiller, and that they anticipated that it would help his pain as well. During a house call many years ago, one of us PL easily diagnosed a 40 year old male complaining of diarrhoea and abdominal cramps for several hours as suffering from gastroenteritis. She was adamant, and her husband was not inclined to express dissent.

Only after promising another house visit free of charge if the symptoms had not improved within 24 hours was the physician allowed to take his leave. The ethical problem with placebo treatment is not that the patient is receiving an ineffective medicine—the placebo, as we have claimed, may be quite effective, just as the standard medication may prove, in any particular case, to be useless or even harmful; furthermore, the placebo will usually have the advantage of producing less undesirable side effects.

The ethical problem most frequently raised regarding the administration of the placebo is that the doctor is deceiving the patient. The patient wants effective treatment; instead he receives a placebo.

Examined carefully, this point may be greatly overstated. The assumption upon which this issue rides is that only through pharmacology or similarly respectable and rational procedures can the doctor aid the patient. This has never been true, and even in an age of evidence based medicine remains untrue. The physician intervenes at many points along the biopsychosocial continuum—through his personality, air of assurance, words of encouragement, offers of help, and resolution of uncertainty.

The placebo is a deception only for those who would reduce treatment to a purely biomedical pursuit. Significantly, disclosing to a patient that he is receiving a placebo will not necessarily diminish its effectiveness. Sustained disclosure, however, might lead to extinction of this conditioned behaviour, and with it the extinction of the placebo effect.

The way that the physician reports the nature of the placebo she is offering is important here, as she tries to maximise the therapeutic effect without being dishonest with the patient. I do not know exactly how it works. I have other pills to offer whose mechanism is clearer, but I am not sure that they will work better for you, and they may also entail more serious side effects.

In case 1 which we presented above, to claim that we deceived the patient would be a narrow perspective indeed of the situation. We told the patient that the injection would assuage the pain; we indeed believed that it would and, perhaps less relevant to the issues at hand, it did. There was nothing dishonest in the communication between doctor and patient.

Some might argue that we are nevertheless involved in deception, because the placebo itself is inert:. The one thing of which we can be absolutely certain is that placebos do not cause placebo effects. This is a winsome rhetorical flourish, and it is wrong.

If, however, the sound waves are interpreted as words, or the placebo as a therapeutic agent, then they may lay equal claim to be included in the causal chain culminating in a beneficial psychophysiological effect. Sometimes a patient will demand to know the name of the pill. In that case he should be told.

He may ask how it works. He should be told that as well. He may refuse the pill. He is within his rights. We do not know if this sort of full disclosure about the placebo might diminish its effect. Empirical studies could provide an answer.